Hugh Garton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hugh Garton has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Alexander R. Judkins
Children's Hospital Los Angeles
59 shared publications - Arul M. Chinnaiyan
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
59 shared publications - Chan Chung
Department of New Biology, DGIST, Daegu, 42988, Republic of Korea.
59 shared publications - Drew Pratt
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, USA
59 shared publications - Fusheng Yang
Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Keck School of Medicine University of Southern California, Los Angeles, USA
59 shared publications - Mariella G. Filbin
Department of Pediatric Oncology, Dana-Farber Boston Children’s Cancer and Blood Disorders Center, Boston, USA
59 shared publications
Latest Publications
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual patients with H3K27M-mutant DMG treated with ONC201.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual patients with H3K27M-mutant DMG treated with ONC201.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
ONC201 dosage chart for patients younger than 18 years of age.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
ONC201 dosage chart for patients younger than 18 years of age.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual cases from historical control datasets.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual cases from historical control datasets.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
VST-transformed gene expression values for all samples and protein-coding genes.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
VST-transformed gene expression values for all samples and protein-coding genes.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Summary of historical control datasets.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Summary of historical control datasets.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.